JP MORGAN/CALL/EVOTEC/26/0.1/20.09.24 Share Price

Warrant

DE000JB9LN70

Market Closed - Börse Stuttgart 15:21:26 28/06/2024 BST
0.001 EUR 0.00% Intraday chart for JP MORGAN/CALL/EVOTEC/26/0.1/20.09.24
1 month-50.00%
3 months-94.74%
Date Price Change
28/06/24 0.001 0.00%
27/06/24 0.001 0.00%
26/06/24 0.001 0.00%
25/06/24 0.001 0.00%
24/06/24 0.001 0.00%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 03:21 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer J.P. Morgan
WKN JB9LN7
ISINDE000JB9LN70
Date issued 21/12/2023
Strike 26
Maturity 20/09/2024 (82 Days)
Parity 10 : 1
Emission price 0.13
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.21
Lowest since issue 0.001
Delta0.13x
Omega 3.716
Premium193.15x
Gearing28.95x
Moneyness 0.3452
Difference Strike 17.02
Difference Strike %+65.48%
Spread 0.06
Spread %98.36%
Theoretical value 0.0310
Implied Volatility 147.78 %
Total Loss Probability 96.73 %
Intrinsic value 0.000000
Present value 0.0310
Break even 26.31 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus